

January 17, 2005

Amendments to the Claims

This listing of claims will replace all prior versions and listings of the claims in the application.

1. (Presently Amended) A transdermal patch for administering a volatile liquid drug transdermally to a patient comprising
 - a) a top backing layer that is impermeable to the drug;
 - b) an intermediate, cast, amine-compatible solid silicone adhesive layer which underlies the backing layer, has a thickness of from about 25 microns to about 100 microns, and contains from about 5 to about 50 wt.% of the drug based on the total dry weight of the drug and adhesive, and is a source in the patch of the drug;
 - c) a solid acrylic adhesive layer having a thickness of from about 25 microns to about 100 microns and comprising a copolymer prepared by copolymerizing (i) vinyl acetate, (ii) methacrylic acid, and (iii) at least one monomer selected from the group consisting of acrylate and methacrylate, and which underlies and is in diffusional contact with the silicone adhesive layer; and
 - d) a removable release liner layer underlying the acrylic adhesive layer,wherein the relative thickness of layers "b" and "c", and the concentration of drug initially present in layer "b" is selected to provide a drug flux profile which is

January 17, 2005

characterized by an initial period during which the flux rises to a level suitable for administering a therapeutic amount of the drug, and a second period during which the drug flux is sustained above said level, said second period lasting for at least twice as long as said initial period, and wherein the amount of drug in the patch is sufficient to provide a therapeutically effective amount of drug to the patient over a period of at least about several hours and wherein the drug is a combination of nicotine and mecamylamine and the patch is capable of administering 0.2 to 1.5 mg nicotine per hour and 0.02 to 1 mg mecamylamine per hour to the patient.

2. - 32. (Canceled)

33. (Presently amended) The patch of Claim 1 28, wherein ~~the drug comprises a mixture of nicotine and mecamylamine~~ the silicone adhesive layer comprises a silicone pressure sensitive adhesive.

34-35. (Canceled)

36. (Presently amended) The patch of Claim 1 3, wherein the patch contains an amount of drug sufficient to provide administration of the drug for a period of up to about 72 hours.

37. - 38. (Canceled)

January 17, 2005

39. (New) A transdermal patch for administering volatile liquid drugs transdermally comprising:

- a) a top backing layer that is impermeable to the drug;
- b) a cast pressure-sensitive silicone adhesive layer which is contiguous to and underlies the backing layer, which contains said drug, and which is a source of the drug for the patch;
- c) a solid pressure-sensitive acrylic adhesive layer which is contiguous to and which underlies and is in diffusional contact with said silicone adhesive layer;
and
- d) a removable release liner underlying the acrylic adhesive layer;

wherein the drug comprises a mixture of nicotine and mecamylamine and the amount of drug in the patch is sufficient to provide a therapeutically effective amount of drug to the patient.